• cancer antigen 19-9
• elevated ca 19-9
• lung cancer with gastrointestinal features
• metastatic non-small cell lung cancer
• tumor biomarkers

• Biomarker
• Drug resistance
• Epigenetics
• Ovarian cancer
• miR

• P30 CA225520 NCI NIH HHS

• Pancreas
• Pancreatic Cyst
• Pancreatic Neoplasms

• PANCAIM
• PANCAID

• attitudes
• behaviors
• cancer screening
• information seeking
• lifestyle
• tumor markers test

• Chinese population
• carbohydrate antigen 19-9
• diabetic kidney disease
• estimated glomerular filtration rate
• urinary albumin-to-creatinine ratio

• acute exacerbation
• idiopathic pulmonary fibrosis; interstitial lung disease
• oncomarker
• tumor marker

• Humans
• Male
• Female
• Retrospective Studies
• Lung Diseases, Interstitial/blood
• Lung Diseases, Interstitial/mortality
• Lung Diseases, Interstitial/diagnosis
• Lung Diseases, Interstitial/physiopathology
• Aged
• Middle Aged
• Prognosis
• Biomarkers/blood
• Disease Progression
• Predictive Value of Tests
• Aged, 80 and over
• Hospitalization
• Risk Factors
• Ferritins/blood
• Keratin-19/blood

• carbohydrate antigen 19-9
• population study
• skeletal muscle mass

• Male
• Humans
• Adult
• Female
• Muscle, Skeletal/physiology
• Sarcopenia/diagnosis
• Sarcopenia/epidemiology
• Carbohydrates

The clinical implication of using serum tumor markers in patients with interstitial lung disease (ILD) is inconclusive. In this retrospective study, we analyzed the data of 1176 subjects (294 with ILDs and 882 healthy controls). Eligible patients were who had at least one or more available tumor marker results [carbohydrate antigen (CA) 19-9, CA 125, and carcinoembryonic antigen (CEA)] with no evidence of malignancies or other benign diseases that could be related to the increasing concentration of the values. The healthy controls selected from a health screening program were also screened for the presence of active cancer, and matched at a ratio of 1:3 with age and sex. The proportion of patients with abnormal values in the ILD group (121, idiopathic pulmonary fibrosis (IPF); 173, non-IPF-ILDs) was higher than in the matched control group (CEA, 21.5% vs. 5.5%; CA 19-9, 27.9% vs. 4.0%; CA 125, 36.4% vs. 2.0%). In the multivariable analysis, higher CEA levels were associated with shorter survival after adjusting for age, sex, lung function, and ILD subtypes (hazard ratio: 2.323, 95% confidence interval: 1.271–4.248, P = 0.006). In subgroup analysis, CEA remained a prognostic factor in patients with non-IPF-ILDs, but not in those with IPF.

Distal cholangiocarcinoma (DCC) presents as one of the relatively rare malignant tumors in the digestive system and has a poor long-term prognosis. Curative resection is currently the most appropriate therapy for patients with DCC because of the lack of effective adjuvant therapies. Therefore, it is important to accurately predict the prognosis for formulating a reasonable treatment plan and avoiding unnecessary surgical trauma.

To minimize the interference of obstructive jaundice on carbohydrate antigen 19-9 (CA19-9) level by adapting CA19-9 to γ-glutamyltransferase (GGT) as an indicator, to determine the strong associations between CA19-9/GGT and postoperative neoplasm recurrence and long-term outcome of DCC.

We enrolled 186 patients who were diagnosed with DCC between January 2010 and December 2019 and performed radical excision with strict criteria as follows in our hospital. Receiver operating characteristic curves were drawn according to preoperative CA19-9/GGT and 1-year survival. Based on this, patients were divided into two groups (group 1, low-ratio, n = 81; group 2, high-ratio, n = 105). Afterwards, by the way of univariate and multivariate analysis, the risk factors influencing postoperative tumor recrudesce and long-term prognosis of patients with DCC were screened out.

Optimum cut-off value of CA19-9/GGT was 0.12. Patients in group 2 represented higher CA19-9 and lymphatic metastasis rate accompanied by lower GGT, when compared with group 1 (P < 0.05). The 1-, 3- and 5-year overall survival rates of patients in groups 1 and 2 were 88.3%, 59.2% and 48.1%, and 61.0%, 13.6% and 13.6%, respectively (P = 0.000). Multivariate analysis indicated that CA19-9/GGT, lymphatic metastasis and tumor differentiation were independent risk factors for tumor recurrence and long-term prognosis of DCC.

Elevation of CA19-9/GGT performed better as a biomarker of aggressive carcinoma and predictor of poor clinical outcomes by reducing the effect of obstruction of biliary tract on CA19-9 concentration in patients with DCC.

• Distal cholangiocarcinoma
• Pancreaticoduodenectomy
• Carbohydrate antigen 19-9
• γ-Glutamyltransferase
• Relapse
• Prognosis

• carbohydrate antigen 19-9
• pancreatic head carcinoma
• pancreatoduodenectomy
• prognosis
• γ-glutamyltransferase

• Beijing Municipal Science & Technology Commission, PR China
• Capital’s Funds for Health Improvement and Research, Beijing, PR China

• Pancreatic head carcinoma (PHC)
• carbohydrate antigen 19-9 (CA19-9)
• pancreaticoduodenectomy
• prognosis
• total bilirubin

Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has a limited number of prognostic factors. Inflammation has been demonstrated to play a key role both in PDAC initiation and progression and several inflammation-based prognostic scores have been investigated in a wide range of malignancies. We compared the most analyzed inflammation-based prognostic scores in order to establish their potential impact on prediction of the outcome in advanced PDAC patients.

A total of 234 advanced PDAC patients undergoing first-line chemotherapy in our institute were retrospectively analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using Kaplan-Meier method and survival differences were evaluated using the log-rank test. Level of statistical significance P was set at 0.05. Only those variables that proved to be associated with statistically significant differences in outcome were compared in multivariate analysis using multiple Cox regression, as to identify their independent role and their relative power against each other.

In the whole cohort, median overall survival (OS) was 8.7 months (95% CI: 7.8–9.4 months), median progression-free survival (PFS) was 3.8 months (95% CI: 3.1–4.2 months). At univariate analysis high systemic immune-inflammation index (SII) was related to shorter OS [hazard ratio (HR) =2.04, 95% CI: 1.59–4.19, P=0.0001] and PFS (HR =1.52, 95% CI: 1.11–2.20, P=0.01). This was maintained at multivariate analysis both for OS (HR =2.11, 95% CI: 1.29–3.46, P=0.003) and PFS (HR =1.64, 95% CI: 1.14–2.37, P=0.008), whereas other inflammation-based scores lost their independent role. Elevated SII (≥1,200) was associated with low albumin levels (P=0.03) and with elevated lactate dehydrogenase (LDH) (P=0.01).

Elevated SII represents an independent negative prognostic factor above all others for both OS and PFS in advanced PDAC patients treated with first-line chemotherapy, thus confirming a pivotal role of systemic inflammation on PDAC progression and on patient outcome.

• Inflammation
• pancreatic cancer
• prognosis
• systemic immune-inflammation index (SII)

The diagnostic performance of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels for multiple-organ cancer screening has not been fully elucidated. However, they are widely used for real-world opportunistic screening of multiple-organ cancers. This study aimed to examine the diagnostic performance of these serum markers in multiple-organ cancer screening. Data from asymptomatic individuals subjected to opportunistic cancer screening were analyzed. The diagnostic performance of CEA and CA 19-9 was assessed for (A) upper/lower gastrointestinal cancers and (B) whole-body cancers (including both gastrointestinal and other organ cancers) using the results of upper/lower gastrointestinal endoscopy and whole-body imaging as reference. Data from 12,349 and 7616 screened individuals were used to assess the diagnostic performance of CEA and CA 19-9 for (A) and (B), respectively. For (A), the sensitivity and positive predictive value (PPV) of CEA (cut-off: 5 ng/mL) were 7.8% and 3.7%, respectively; those of CA19-9 (cut-off: 37 U/mL) were 7.4% and 2.7%, respectively. For (B), the sensitivity and PPV of CEA were 6.6% and 4.1%, respectively, and those of CA19-9 were 10.8% and 5.8%, respectively. Considering even multiple cancers, the sensitivity and PPV of CEA and CA 19-9 were low, thus confirming their limited usefulness in multiple-organ cancer screening.

• basal cell carcinoma
• cancer
• carbohydrate 19-9 antigen
• multiple tumours
• nonmelanoma skin cancer
• occult primary malignancies
• squamous cell carcinoma

• CA19-9
• CEA
• ERCP
• biliary obstruction
• biliary stenosis
• cholangiocarcinoma
• cholangiopathy
• cholangitis
• cholestasis
• pancreatic cancer
• pancreatitis

• autopsy
• carbohydrate antigen 19-9
• coagulation abnormalities
• elderly
• gastric cancer
• immunohistochemistry